← Back to Clinical Trials
Recruiting NCT05578560

NCT05578560 The Use of Virtual Reality in Rehabilitation in Patients After Vestibular Schwannoma Surgery.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05578560
Status Recruiting
Phase
Sponsor Charles University, Czech Republic
Condition Acute Peripheral Vestibulopathy Following Surgical Procedure
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2020-01-01
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Prehabituation3D optokinetic stimulation in virtual reality spaceVestibular training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2020-01-01 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Resection of the vestibular schwannoma leads to acute peripheral or combined vestibular loss caused by a surgical lesion to the branches of the vestibular nerve and, less frequently also the lesion of the cerebellum. The lesion presents in patients with postural instability, vertigo, oscillopsia, and vegetative symptoms that may accompany it. The organism reacts to this state with the process of central compensation with the significant role of the cerebellum. The goal of the rehabilitation is to support this process and thus to make recovery faster and more efficient since not all patients are capable of complete restoration of the vestibular function. Up to date, rehabilitation includes, apart from the specific vestibular exercise, also the possibility of modern techniques using virtual reality space and prehabituation. Thanks to prehabituation, i.e., chemical labyrinthectomy with intratympanically installed gentamicin, the timing of the origin of the acute vestibular loss and the surgical procedure is separated. Therefore, there is a chance of achieving vestibular compensation before vestibular schwannoma removal. In the last decade, due to the advances in technology in the field of computer games and the applications for smartphones, the tools for virtual reality have become less expensive and more available in common praxis. Virtual reality is a technique for generating an environment that can strengthen three-dimensional optokinetic stimulation, subsequently the process of central compensation. Overall, it may shorten the time of recovery after the surgery and improve patients' quality of life.

Eligibility Criteria

Inclusion Criteria: * Vestibular Schwannoma appropriate to surgical resection Exclusion Criteria: * Eye disorder * Oculomotor disorder in patient history * Nerve palsy other than n. VIII, n. VII.

Contact & Investigator

Central Contact

Marketa Bonaventurova

✉ bonaventurova.m@seznam.cz

📞 +420722983690

Principal Investigator

Markéta Bonaventurová

PRINCIPAL INVESTIGATOR

Department of ENT and Head and Neck Surgery, Charles University in Prague and Motol University Hospital

Frequently Asked Questions

Who can join the NCT05578560 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Peripheral Vestibulopathy Following Surgical Procedure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05578560 currently recruiting?

Yes, NCT05578560 is actively recruiting participants. Contact the research team at bonaventurova.m@seznam.cz for enrollment information.

Where is the NCT05578560 trial being conducted?

This trial is being conducted at Prague, Czechia.

Who is sponsoring the NCT05578560 clinical trial?

NCT05578560 is sponsored by Charles University, Czech Republic. The principal investigator is Markéta Bonaventurová at Department of ENT and Head and Neck Surgery, Charles University in Prague and Motol University Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology